CLVS Clovis Oncology Inc.

76.01
-0.73  -1%
Previous Close 76.74
Open 78.53
Price To book 10.81
Market Cap 3715319698
Shares 48,879,354
Volume 2,403,103
Short Ratio 5.33
Av. Daily Volume 1,654,024

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171003975
  2. 8-K - Current report 171000037
  3. 8-K - Current report 17955304
  4. S-8 - Securities to be offered to employees in employee benefit plans 17938379
  5. 8-K - Current report 17929054

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial planned for 2017.
Opdivo and Rubraca
Castration-resistant prostate cancer (mCRPC)
Phase 3 trial planned for 2017.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 trial planned for 2017.
Opdivo and Rubraca
Ovarian Cancer - First-line maintenance treatment
Phase 3 trial open for enrollment - February 22, 2017.
Rucaparib - TRITON3
Castration-Resistant Prostate Cancer
Phase 1b/2 trial initiated January 2016
Rociletinib in combination with atezolizumab
EGFR-mutant non-small cell lung cancer
Phase 3 data released June 20 2017 - primary endpoint met. sNDA filing due by the end of October 2017. Late breaker at ESMO September 8, 2017.
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
PDUFA date was June 28, 2016. Company expect CRL. Phase 3 TIGER-3 also terminated.
Rociletinib
Mutant EGFR T790M-positive lung cancer
Development discontinued
Lucitanib
Breast cancer
Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017.
Rucaparib ARIEL2
Cancer - ovarian second line

Latest News

  1. Clovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher
  2. Today's Research Reports on Stocks to Watch: Dimension Therapeutics and Clovis Oncology
  3. Clovis Up 10% On Double Normal Volume
  4. So Much PARP Inhibitor Deal Hype, So Little Payoff
  5. Clovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet
  6. Should You Keep Your Portfolio Healthy with Biotech ETFs?
  7. Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology
  8. A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It
  9. Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers
  10. Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017
  11. Why Clovis Oncology Fell 7.1% in August
  12. Clovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound?
  13. See what the IHS Markit Score report has to say about Clovis Oncology Inc.
  14. Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition
  15. After Gilead's Acquisition Of KITE, Who Gets Gobbled Up Next?
  16. Clovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress
  17. Here's Why Clovis Stock Is Up Almost 60% So Far in 2017
  18. Tesaro: Losing Its Edge?
  19. Ovarian Cancer Market Still Up For Grabs

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171003975
  2. 8-K - Current report 171000037
  3. 8-K - Current report 17955304
  4. S-8 - Securities to be offered to employees in employee benefit plans 17938379
  5. 8-K - Current report 17929054
  6. 424B5 - Prospectus [Rule 424(b)(5)] 17922266
  7. 424B5 - Prospectus [Rule 424(b)(5)] 17918584
  8. 8-K - Current report 17917425
  9. CT ORDER - Confidential treatment order 17910981
  10. 8-K - Current report 17900998